Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia

Leuk Res. 2012 Apr;36(4):e71-3. doi: 10.1016/j.leukres.2011.12.010. Epub 2012 Jan 9.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Area Under Curve
  • Cytarabine / administration & dosage
  • Cytarabine / adverse effects
  • Cytarabine / analogs & derivatives
  • Cytarabine / pharmacokinetics
  • Female
  • Half-Life
  • Humans
  • Idarubicin / administration & dosage
  • Idarubicin / adverse effects
  • Idarubicin / pharmacokinetics
  • Leukemia, Myeloid, Acute / drug therapy*
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Young Adult

Substances

  • Cytarabine
  • 5'-oleoyl cytarabine
  • Idarubicin